| Patents for A61P 13 - Drugs for disorders of the urinary system (56,135) |
|---|
| 07/14/2005 | WO2004048386A9 THIENO[3,2-b]PYRIDINE-6-CARBONITRILES AND THIENO[2,3-b]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS |
| 07/14/2005 | WO2004047838A2 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents |
| 07/14/2005 | WO2003059294A3 Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor |
| 07/14/2005 | WO2003029424A3 Novel proteins and nucleic acids encoding same |
| 07/14/2005 | US20050154232 Nitrosation of the diphenylamine with an alkali metal nitrite in an acidic medium; the nitrosodiphenylamines increase the bioavailability of endothelial nitrogen monoxide; the diphenylamines are used as antioxidants and free radical scavengers; insulin resistance |
| 07/14/2005 | US20050154231 Tamsulosin derivative |
| 07/14/2005 | US20050154230 Urea derivatives |
| 07/14/2005 | US20050154049 Administering an ultrasonic contrast agent; imaging tissue; medical diagnosis |
| 07/14/2005 | US20050154039 5-Sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine |
| 07/14/2005 | US20050154025 6-[4-(fluoro- or trifluoromethyl)pyridyl-4-(p-fluorophenyl)-5-methylimidazol-2-yl] pyridones; cyclization of 1-phenyl-1-pyridyl-1,2-diaminopropanes with an acid, amidine, or nitrile compound; neuropeptide Y receptor antagonists; cardiovascular and central nervous system disorders, metabolic diseases |
| 07/14/2005 | US20050153973 (4R)-3-(2-{[8-(2-Pyrimidinyl)-8-azabicyclo[3.2.1]oct-3-yl]exo-amino}acetyl)thiazolidine-4-carbonitrile; enzyme inhibitors; diabetes |
| 07/14/2005 | US20050153902 Inhibitors of integrin avb6 |
| 07/14/2005 | US20050153888 oligopeptides capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM), used for treatment of normal, degenerated and damaged NCAM presenting cells |
| 07/14/2005 | US20050153315 Nucleotide sequences coding polypeptide comprising methylarginase activities for use in identifying modulator for prevention and treatment of ischemia-reperfusion injuries, cancer, hypotension, multi-organ failure, arthritis, skin, inflammatory, cardiac and/or migraine disorders |
| 07/14/2005 | US20050153286 Calcium channel polypeptide for use in identifying modulator for prevention and treatment of cell proliferative disorders of the kidney |
| 07/14/2005 | US20050152926 For immunization and/or diagnosis; eg pneumonia, cardiovascular diseases, atherosclerosis, bronchitis |
| 07/14/2005 | CA2548316A1 Preparation of r-5-(2-(2-ethoxyphenoxyetylamino)propyl)-2-methoxybenzenesulphonamide hydrochloride of high chemical |
| 07/14/2005 | CA2507343A1 Pharmaceutical composition comprising beta-3-adrenoceptor agonists and antimuscarinic agents |
| 07/13/2005 | EP1553098A1 Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| 07/13/2005 | EP1553097A1 Quinazoline derivatives as angiogenesis inhibitors and intermediates therefore |
| 07/13/2005 | EP1553085A1 Cyclic amine derivatives and their use as drugs |
| 07/13/2005 | EP1553084A1 Piperidine derivative, process for producing the same, and use |
| 07/13/2005 | EP1553078A1 Calcium receptor-active compounds |
| 07/13/2005 | EP1553074A1 Fused benzene derivative and use |
| 07/13/2005 | EP1552842A1 Bicyclic pyrimidine derivatives |
| 07/13/2005 | EP1552830A1 Drug composition for prevention or inhibition of advance of diabetic complication |
| 07/13/2005 | EP1552825A1 Therapeutic agent for overactive bladder |
| 07/13/2005 | EP1551848A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors |
| 07/13/2005 | EP1551837A1 Phosphodiesterase 4 inhibitors |
| 07/13/2005 | EP1551803A1 Azabicyclo derivatives as muscarinic receptor antagonists |
| 07/13/2005 | EP1551461A2 Azo compounds for type i phototherapy |
| 07/13/2005 | EP1551456A1 Pharmaceutical composition for prevention and treatment of kidney diseases |
| 07/13/2005 | EP1551434A2 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 07/13/2005 | EP1551394A1 Treatment of lower urinary tract symptoms associated with overactive bladder in men and women |
| 07/13/2005 | EP1551369A2 Combination therapy for treatment of fibrotic disorders |
| 07/13/2005 | EP1235802B1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 07/13/2005 | EP1207860A4 Controlled release pellet formulation |
| 07/13/2005 | EP1144364B1 Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4 |
| 07/13/2005 | CN1639317A Probiotic lactobacillus salivarius strains |
| 07/13/2005 | CN1639180A Aryl 5-thio-beta-D-glucopyranoside derivatives and remedies for diabetes containing the same |
| 07/13/2005 | CN1639161A Alkyne-aryl phosphodiesterase-4 inhibitors |
| 07/13/2005 | CN1639159A N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as DDP-IV inhibitors |
| 07/13/2005 | CN1639158A Thiazole derivatives as NPY receptor antagonists |
| 07/13/2005 | CN1639146A Fused tricyclic heterocycles useful for treating hyper-proliferative disorders |
| 07/13/2005 | CN1639145A Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders |
| 07/13/2005 | CN1639132A N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
| 07/13/2005 | CN1639130A Process for producing fused imidazole compound, reformatsky reagent in stable form, and process for producing the same |
| 07/13/2005 | CN1639126A Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 07/13/2005 | CN1639125A New inhibitors of histone deacetylase |
| 07/13/2005 | CN1639124A Aminotetralin derivatives as muscarinic receptor antagonists |
| 07/13/2005 | CN1639119A Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors |
| 07/13/2005 | CN1638800A Human monoclonal antibodies against CD30 |
| 07/13/2005 | CN1638799A Human mast cell-expressed membrane proteins |
| 07/13/2005 | CN1638796A Methods of administering anti-TNF alpha antibodies |
| 07/13/2005 | CN1638788A Stabilized albumin preparaions |
| 07/13/2005 | CN1638778A Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer |
| 07/13/2005 | CN1638760A Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| 07/13/2005 | CN1638753A Potentiation of therapeutic effects of fatty acids |
| 07/13/2005 | CN1638650A Composition improving age-related physiological deficits and increasing longevity |
| 07/13/2005 | CN1637018A Novel effectors of dipeptidyl peptidase IV |
| 07/13/2005 | CN1637015A 17alpha-alkyl-17beta-oxy-estratrienes, uses thereof and pharmaceutical preparations |
| 07/13/2005 | CN1636994A Process of preparing alkali metal salys of hydrophobic sulfonamides and alkali metal salt produced thereby |
| 07/13/2005 | CN1636991A Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 07/13/2005 | CN1636983A Substituted heterocyclic compounds |
| 07/13/2005 | CN1636967A Noval compounds, their use and preparation |
| 07/13/2005 | CN1636593A Novel effectors of dipeptidyl peptidase IV |
| 07/13/2005 | CN1636572A Compositions and methods for treatment of mitochondrial diseases |
| 07/13/2005 | CN1636559A Ethers of o-desmethyl venlafaxine |
| 07/13/2005 | CN1210273C Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods |
| 07/13/2005 | CN1210262C Method for preparing methylsulfonate trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperid-1-yl)-1-propanol |
| 07/13/2005 | CN1210251C Substituted nor bornylamion derivatives, method for production thereof, use thereof and medicaments containing said compounds |
| 07/13/2005 | CN1210066C Cloning pigs using donor nuclei from differentiated cells |
| 07/12/2005 | US6917616 Method and apparatus for reduction and restoration of data elements pertaining to transmitted data packets in a communications network |
| 07/12/2005 | US6916927 Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′-monophosphate phosphodiesterase (cGMP-PDE5) for the treatment of sexual dysfunction |
| 07/12/2005 | US6916923 Method for synthesizing pyrazolobenzodiazepines |
| 07/12/2005 | US6916848 Compounds for the treatment of metabolic disorders |
| 07/12/2005 | US6916834 Preparations and use of an Ah receptor ligand, 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester |
| 07/12/2005 | US6916832 Nitrogen compounds such as 8,9-dihydroxy-1,2,3,11b-tetrahydro-chromeno(4,3,2-de)isoquinoline hydrobromide, administered for prophylaxis of nervous system disorders |
| 07/12/2005 | US6916828 Irritiable bowel syndrome; respiartory system disorders; antihistamines; gastrointestinal disorders |
| 07/12/2005 | US6916815 C-6 modified indazolylpyrrolotriazines |
| 07/12/2005 | US6916809 Heterocyclic acridone inhibitors of IMPDH enzyme |
| 07/12/2005 | US6916807 Triaryl-oxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 07/12/2005 | US6916485 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar |
| 07/12/2005 | CA2341739C Quinolin-2-one derivatives useful as anticancer agents |
| 07/12/2005 | CA2298142C Soya extract, process for its preparation and pharmaceutical composition |
| 07/07/2005 | WO2005060939A2 Controlled-release pharmaceutical formulation |
| 07/07/2005 | WO2004045554A3 Cytomodulating peptides for treating interstitial cystitis |
| 07/07/2005 | WO2004004779A8 Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycine |
| 07/07/2005 | WO2003089583A3 Tissue specific genes and gene clusters |
| 07/07/2005 | US20050148664 therapy of NF-kappaB mediated diseases; mitochondrial diseases; transplantation medicine |
| 07/07/2005 | US20050148636 Useful aroyl pyrrole heteroaryl methanones and methanols |
| 07/07/2005 | US20050148625 Use of estrogen antagonists and estrogen agonists inhibiting pathological conditions |
| 07/07/2005 | US20050148624 Enzyme inhibitors with isoquinolinone structures |
| 07/07/2005 | US20050148608 Chymase enzyme inhibitors for drugs in vascular systems using sulfonylurea derivatives |
| 07/07/2005 | US20050148591 Tartrate salts of 5,8,14-triazatetracyclo [10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen and pharmaceutical compositions thereof |
| 07/07/2005 | US20050148575 (Di)Azepino[5,4,3-cd]benzothiophenes; poly(ADP-ribose) polymerase (PARP) and glycohydrolase (PARG) inhibitor; antiinflammatory; protects cells, tissue and organs against the ill-effects of reactive free radicals and nitric oxide, and damage following focal ischemia and reperfusion injury |
| 07/07/2005 | US20050148550 Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine compounds |
| 07/07/2005 | US20050148527 Catalytic nucleic acids; ribozymes; translation inhibition; gene expression inhibition; for treating cardiovascular disease; for neovascularization induction in heart tissue |
| 07/07/2005 | US20050148014 Regulation of human P2Y1-like G protein-coupled receptor |
| 07/07/2005 | US20050148012 BPC-1: a secreted brain-specific protein expressed and secreted by prostate and bladder cancer cells |